Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 124, Issue 11, pp 615–620 | Cite as

The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis

  • Guiqui Wang
  • Zhiwei Dong
  • Guangwei Xu
  • Zhihua Yang
  • Chengchao Shou
  • Naiqin Wang
  • Tong Liu
ORIGINAL PAPER

Abstract

Vascular endothelial growth factor (VEGF), a very important in the process of tumor angiogenesis, was chosen as a target in a study to determine whether manipulation of angiogenesis with antibody against VEGF may interrupt tumor growth and metastasis. Anti-VEGF antibody was obtained from immunized rabbits, purified on an affinity column, and identified as neutralized antibody by Mile's assay. IVTA2MA891, a murine spontaneous breast cancer with a high rate of metastasis in lung in TA2 × 615 F1 mice, was chosen as an animal model in this study, because of the high expression of VEGF in the primary tumor as well as in the lung metastatic tumor. The anti-VEGF antibody could inhibit growth of S180 sarcoma in a dose-dependent manner, and the inhibition rate could reach 41.0% with a dose of 200 μg mouse−1 day−1. Anti-VEGF antibody could inhibit tumor growth by 76.2% in nude mice bearing human gastric cancer (MGC 803). When anti-VEGF antibody was combined with 131I-3H11, a murine monoclonal antibody conjugated with 131I, only one of five nude mice developed tumor and 84.0% more inhibition of tumor growth was obtained in comparison with treatment by 131I-3H11 alone. The growth of the primary tumor was inhibited by 44.0% and the number and size of the metastatic foci in the lungs were reduced by 73.0% and 83.7% respectively in the animal model, with a high rate of metastasis in lung. The anti-VEGF antibody may be potentially useful for clinical treatment of cancer and metastasis.

Key words Vascular endothelial growth factor Antibody Tumor Angiogenesis Metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Guiqui Wang
    • 2
  • Zhiwei Dong
    • 1
  • Guangwei Xu
    • 2
  • Zhihua Yang
    • 1
  • Chengchao Shou
    • 2
  • Naiqin Wang
    • 2
  • Tong Liu
    • 2
  1. 1.Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Panjiayuan, ChaoYang District, Beijing 100021, Beijing, P.R. China e-mail: wangguiq@public.bta.net.cn Tel.: +861-(0)10-67714346CN
  2. 2.Beijing Institute for Cancer Research, Beijing Medical University, Beijing 100021, P.R. ChinaCN

Personalised recommendations